Product Description
CD55 Antibody [F4-29D9] | 33-342 | ProSci
Host: Mouse
Reactivity: Human
Homology: N/A
Immunogen: Human umbilical vein endothelial cells (HUVEC) were used as the immunogen for the CD55 antibody.
Research Area: Immunology
Tested Application: WB, Flow, IF
Application: Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 1-2 ug/ml
Optimal dilution of the CD55 antibody should be determined by the researcher.
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein G affinity chromatography
Clonality: Monoclonal
Clone: F4-29D9
Isotype: IgG1, kappa
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: Decay-accelerating factor, CD55 molecule decay accelerating factor for complement (Cromer blood group) , CD55, CR, TC, CROM
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: Recognizes a single chain glycoprotein of 70kDa, identified as CD55 (also known as decay accelerating factor, DAF) . This mAb was clustered in Kobe at the Sixth International Workshop on Human Leukocyte Differentiation Antigens as F429D-9 (N-L120) . CD55/DAF is widely expressed on cells throughout the body including leukocytes, erythrocytes, epithelium, endothelium, and fibroblasts. It is a Glycosyl phosphatidylinositol anchored (GPI-anchored) member of the membrane bound complement regulatory proteins that inhibit autologous complement cascade activation. It prevents the amplification steps of the complement cascade by interfering with the assembly of the C3-convertases, C4b2a and C3bBb, and the C5-convertase, C4b2a3b and C3bBb3b. CD55 also serves as receptor for CD97 and for echovirus and Coxsackie B virus. Anti-CD55 can be used as marker for paroxysmal nocturnal hemoglobinuria (PNH) .